Takeda has partnered with Biological E. Limited in India to scale up manufacturing of its dengue vaccine, TAK-003. The collaboration aims to increase availability of the vaccine in India and globally. Dengue fever remains a significant public health issue, with millions of cases reported annually. The World Health Organization has set a goal of achieving zero case-fatality rate from dengue by 2030.
This partnership is part of Takeda’s strategy to improve access to its vaccine through local production. Biological E. Limited is a key player in India’s vaccine industry. The agreement supports efforts to combat dengue, which is transmitted by mosquitoes and can lead to severe illness.
The move highlights growing collaboration between international pharmaceutical companies and Indian manufacturers. It also reflects the increasing focus on addressing tropical diseases through localized production. The vaccine is currently in various stages of regulatory review in different countries.
